NeuroSense Therapeutics Ltd. NRSN
6.95
(0.45)
(6.08%)
as of 25 Sep
- Market cap
- $14.0M
- P/E
- 0.0×
Follow NRSN
Insider Buys
alert about insiders buying in the last 12 month
| Jun '25 | Sep '24 | Jun '24 | Mar '24 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | 705.26% |
+8 more TTM periods Free account |
|
| 0.00% | 0.00% | 0.00% | (426.84%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 444.61% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | — | 0.00 | 0.00 | |
Free Cash Flow |
(18.18) | — | (15.73) | — | |
Capital Expenditures |
(0.06) | — | (0.07) | — | |
| Other line items | |||||
Cash ROIC |
(9,533.68%) | 0.00% | 3,691.75% | 0.00% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Share Based Compensation of Revenue |
0.00% | — | — | — | |
Interest Coverage |
— | — | — | 0.00 | |
Operating CF/Net income |
0.00 | — | 0.00 | 0.00 | |
Depreciation/Fixed assets |
1.70 | 0.00 | 1.32 | 0.00 | |
Capex/Depreciation |
(0.59) | — | (0.74) | — | |
Revenue per Share |
— | — | — | 0.00 | |
Operating CF per Share |
0.00 | — | 0.00 | 0.00 | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | — | |
Net Profit Margin |
— | — | — | 0.00% |
Columns are period end dates